Market capitalization | $1.89b |
Enterprise Value | $1.67b |
P/E (TTM) P/E ratio | 44.85 |
EV/FCF (TTM) EV/FCF | 36.98 |
EV/Sales (TTM) EV/Sales | 12.55 |
P/S ratio (TTM) P/S ratio | 14.19 |
P/B ratio (TTM) P/B ratio | 2.42 |
Revenue growth (TTM) Revenue growth | -28.55% |
Revenue (TTM) Revenue | $133.48m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
6 Analysts have issued a Ligand Pharmaceuticals Incorporated forecast:
6 Analysts have issued a Ligand Pharmaceuticals Incorporated forecast:
Dec '23 |
+/-
%
|
||
Revenue | 131 131 |
33%
33%
|
|
Gross Profit | 88 88 |
26%
26%
|
|
EBITDA | 47 47 |
16%
16%
|
EBIT (Operating Income) EBIT | 9.82 9.82 |
24%
24%
|
Net Profit | 52 52 |
256%
256%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Todd Davis |
Employees | 58 |
Founded | 1987 |
Website | www.ligand.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.